Informing the debate on Britain’s electricity system

Challenge

The electricity sector is currently undergoing unprecedented changes, including obligations to decarbonise and pressure to keep bills down. With old coal being driven off the system, new nuclear given the go-ahead, prices reaching new highs and lows, and clean energy overtaking fossil fuels for the first time, there is an increasing need for a strong evidence base and robust analysis.

Solution

Imperial researchers, including Drs Iain Staffell and Rob Gross (Centre for Environmental Policy) and Professors Richard Green (Imperial Business School) and Tim Green (Director of the Energy Futures Lab), are providing new empirical evidence to contribute to the UK energy debate. Commissioned by Drax Group, operator of the UK’s largest power station, based at Selby in North Yorkshire, which now predominantly uses sustainable biomass to generate 17% of the UK’s renewable electricity, the Imperial team is using its combined analytical expertise to power www.electricinsights.co.uk, an interactive website and quarterly report.

Electric Insights brings to life the wealth of raw data made publicly available by National Grid and Elexon, which run the electricity network and balancing market respectively. Using information gathered from 2009 to present day, it focuses on supply and demand, prices, emissions, the performance of the various generation technologies and the network that connects them. The website and reports are regularly referred to in the press and shed an informative light on the sources and implications of Britain’s electricity supply for both government and the industry.

Share post:

 

Related case studies

 

Structures under extreme loading

Structures under extreme loading

The consultants shared their expertise in seismic assessment and design to support the development of EN1998, also known as Eurocode 8. read more

Cystic Fibrosis clinical advisory board

Cystic Fibrosis clinical advisory board

Our consultants shared their expertise in Cystic Fibrosis (CF), drug development and clinical trials to help Proteostasis Therapeutics assess the combination of compounds aimed at treatments to improve lung function. read more

Global adoption and regulation of electronic medical records

Global adoption and regulation of electronic medical records

Our consultants shared their expertise in clinical medicine to help IMS Health to assess the adoption, governance and regulatory landscape of electronic medical records (EMR) at different levels of healthcare systems around the world. read more